New Research on NOACs: Which has More Bleeding Risk―Which is Safer?
Do you take the anticoagulant, Xarelto? Or one of the newer NOACs? Which is safest? Which has the least GI bleeding?
NOACs Research Study Results
A Mayo Clinic study indicated that the risk of gastrointestinal (GI) bleeding is higher for patients taking Xarelto than for other anticoagulants in its class.
The researchers compared the gastrointestinal (GI) safety profile of three rival oral anticoagulants: Xarelto (rivaroxaban), Pradaxa (dabigatran) and Eliquis (apixaban). All of the patients in the study had Atrial Fibrillation.
Bleeding occurrence: GI bleeding occurred more frequently in patients taking Xarelto compared to Pradaxa (approximately 20% increased risk), while Eliquis had the lowest GI bleeding risk.
Age factor: They also found that the risk of GI bleeds increased with age. In particular, patients over the age of 75 were at an increased risk.
Safety: Eliquis had the most favorable GI safety profile, even among very elderly patients, and Xarelto had the least favorable.
NOAC drug manufacturers: Xarelto (Bayer/Janssen Pharmaceuticals), Pradaxa (Boehringer Ingelheim) and Eliquis (Bristol-Myers Squibb).
Reminder: Oral Anticoagulants are High Risk Medications
Oral anticoagulants are not like taking vitamins. They are considered high risk medications. They work by causing or increasing bleeding and can potentially cause serious and uncontrolled bleeds.
But they are certainly better than having an A-Fib stroke which can kill or severely disable. This study only examined GI bleeds. But oral anticoagulants can have other bad effects.
About Pradaxa (dabigatran)
Pradaxa in its clinical trial had more GI bleeds and indigestion (dyspepsia) than warfarin. The Pradaxa fact sheet states “In addition to bleeding, Pradaxa can cause stomach upset or burning, and stomach pain.”
Research: Nearly two out of five people (35%) could not tolerate Pradaxa, which is a high rate of adverse reactions. Patients on Pradaxa 150mg had an increased incidence of gastrointestinal adverse reactions (35%/yr) compared to warfarin (24%/yr).
Reversal agent: On the other hand, Pradaxa is the only anticoagulant that currently has an FDA-approved reversal agent.
If you’re taking Pradaxa (dabigatran), watch out for indigestion, burning, stomach pain and weight loss. Based on the clinical trial data, there is a danger that dabigatran over time may cause long-term damage to the gastrointestinal system.
These statements don’t capture the actual human toll that Pradaxa can produce for some—burning throat, roiling intestines, diarrhea, burning anus, lasting intestinal damage, etc.
About Xarelto (rivaroxaban)
Xarelto lawsuits: There are currently nearly 15,000 lawsuits in the U.S. against the maker of Xarelto (Janssen Pharmaceuticals) not just for GI bleeds but for other side effects such as brain and rectal bleeds.
Xarelto and the other new anticoagulants (NOACs) have not been around long enough to determine their long-term effects.
NOACs vs Warfarin: We do know that long-term use of warfarin risks hemorrhagic strokes and microbleeds which lead to dementia. (See Watchman Better Than Lifetime on Warfarin) Will Xarelto have similar long-term effects? We just don’t know, but intuitively one would expect so.
Safest but no reversal agent: If you have to take one of the new oral anticoagulants, this study indicates that Eliquis is the safest for GI bleeds. But unlike Pradaxa, Eliquis doesn’t currently have an FDA-approved reversal agent. There are reversal agents in the FDA pipeline (which I thought would have been approved by now).
The Bottom Line: Eliquis Tested the Best
So, should you switch to Eliquis? This is a decision only you and your doctor can make. First, whether or not to be on an anticoagulant, and if so, which one. This is one of the most difficult decisions you and your doctor must make. Note: you should revisit your choice from time to time as you and your risk can change over time.